Horizon Bancorp reported a strong Q3 2026 with net income of $28.7 million ($0.56 per share), beating expectations. The bank maintained robust profitability with a return on assets of 1.73% and return on equity of 15.61%, alongside a stable net interest margin of 4.37%. Asset quality remains solid, with nonperforming loans at just 0.72%. Management hinted at potential dividend increases or share buybacks in 2027 while keeping an eye on commercial real estate risks and regional economic conditions. This performance supports Horizon Bancorp as a buy, especially given its forward price-to-earnings ratio under 10.
Horizon Bancorp's strong Q3 2026 results provide context for financial sector performance. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 29, 2026 20:12 WIB: of 142 priced Financials-sector US stocks tradable on Pluang, 102 rose and 35 fell today. Notable movers include BTBT (Bit Digital Inc) at USD 0.93 with a 1-day change of -3.65% and Pluang order activity of 83% Sell / 17% Buy, LU (Lufax Holding Ltd) at USD 7.88 with a 1-day change of -3.55% and Pluang order activity of 96% Sell / 4% Buy, and BMNR (BitMine Immersion Technologies Inc. Common Stock) at USD 21.36 with a 1-day change of -3.13% and a typical hold time on Pluang of 4 Days.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
